Myeloma MRD Flow Panel
Alternative name:
Myeloma Measurable/Minimal Residual Disease
Methodology
Flow cytometry
Test Description and clinical significance
Probes/Genes
CD19, CD27, CD45, CD56, CD81, CD117, CD138, cKappa, cLambda, cVS38c
Disease:
Multiple Myeloma
Minimal residual disease (MRD) in myeloma is an independent predictor of progression-free survival (PFS)1-3 and is under consideration as a surrogate trial endpoint to improve the identification of effective treatments,4,5 particularly for frontline trials, which now require 5 to 10 years of follow-up to identify survival differences.
If clonal, FISH Myeloma panel is recommended.
Specimen Requirements
Collection:
Peripheral blood: 4-5 mL in Green top (sodium heparin) tube preferred, OR purple top (EDTA) tube
Bone marrow aspirate: 2-3mL in Green top (sodium heparin) tube preferred, OR purple top (EDTA) tube
Stability:
Peripheral blood: 48 hours
Bone marrow aspirate: 48 hours
Unacceptable Conditions:
Specimen submitted is in the incorrect anticoagulant. Specimen received after the stability date. Gross hemolysis. Frozen specimen. Insufficient specimen. Unlabeled. Left un-refrigerated for an extended period.
Storage & Transport
If testing is expected to occur in less than eight hours, specimens must be transported between 18°C and 25°C
If testing is expected to occur in greater than eight hours, specimens must be transported with cold packs to maintain specimens between 2-8°C prior to testing
CPT(s)
88184x1, 88185x9, 88188x1
New York Approved
TBD
TAT
24 hours from specimen receipt
Levels of Service
Global
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
